Alk-001 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 301 | 黄斑ジストロフィー | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04239625 (ClinicalTrials.gov) | December 20, 2019 | 11/1/2020 | Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) | A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease | Stargardt Disease;Stargardt Macular Degeneration;Stargardt Macular Dystrophy;Autosomal Recessive Stargardt Disease 1 (ABCA4-related) | Drug: ALK-001 | Alkeus Pharmaceuticals, Inc. | NULL | Enrolling by invitation | 8 Years | 70 Years | All | 140 | Phase 2 | United States |
| 2 | NCT02402660 (ClinicalTrials.gov) | August 2015 | 9/3/2015 | Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease | A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease | Stargardt Disease;Stargardt Macular Degeneration;Stargardt Macular Dystrophy;Autosomal Recessive Stargardt Disease 1 (ABCA4-related) | Drug: ALK-001;Drug: Placebo | Alkeus Pharmaceuticals, Inc. | NULL | Recruiting | 8 Years | 70 Years | All | 140 | Phase 2 | United States |
| 3 | NCT02230228 (ClinicalTrials.gov) | April 2014 | 27/8/2014 | Phase 1 Safety Study of ALK-001 in Healthy Volunteers | A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers | Stargardt Disease;Age-related Macular Degeneration;Other Retinal Dystrophies | Drug: ALK-001 (No generic name) | Alkeus Pharmaceuticals, Inc. | NULL | Completed | 21 Years | 70 Years | Both | 40 | Phase 1 | NULL |